We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Much You'd Have If You Invested $1000 in Novo Nordisk a Decade Ago
Read MoreHide Full Article
For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and industries.
FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks.
What if you'd invested in Novo Nordisk (NVO - Free Report) ten years ago? It may not have been easy to hold on to NVO for all that time, but if you did, how much would your investment be worth today?
Novo Nordisk's Business In-Depth
With that in mind, let's take a look at Novo Nordisk's main business drivers.
Bagsværd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market with a full portfolio of GLP-1 receptor agonists, modern insulins and human insulins. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.
Novo Nordisk operates through two segments: Diabetes and obesity care and Rare diseases. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Rare diseases segment includes hemophilia, growth hormone therapy and hormone replacement therapy.
Novo Nordisk’s most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.
Wegovy, Novo Nordisk’s other obesity care product, was approved by the FDA in June 2021, following which it faced supply issues in the United States, which led to a decline in sales upon launch. However, the issue was resolved by Novo Nordisk, making all dose strengths of Wegovy available in the United States in December 2022. The company is also looking to expand the drug’s indication as an adjunctive treatment for the prevention of major adverse cardiovascular events (MACEs) in adults over a period of up to five years, as well as in the treatment of heart failure and obesity.
In October 2022, Novo Nordisk acquired Forma Therapeutics for $1.1 billion. Forma Therapeutics is a company focused on providing innovative treatment to transform the lives of patients suffering from sickle cell disease (SCD) and rare blood disorders. The acquisition of the company along with Forma’s lead development candidate, etavopivat, complements Novo Nordisk’s vision to accelerate its scientific presence and pipeline in hemoglobinopathies.
Novo Nordisk generated revenues of DKK 177 billion in 2022 compared with DKK 141 billion in 2021. Revenues increased by 26% in Danish kroner and 16% at the currency exchange rate.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Novo Nordisk, if you bought shares a decade ago, you're likely feeling really good about your investment today.
A $1000 investment made in November 2013 would be worth $5,961.03, or a gain of 496.10%, as of November 22, 2023, according to our calculations. This return excludes dividends but includes price appreciation.
In comparison, the S&P 500 gained 152.70% and the price of gold went up 54.56% over the same time frame.
Analysts are forecasting more upside for NVO too. Novo Nordisk beat earnings and revenue estimates in Q3 due to higher GLP-1 product sales. It has one of the broadest diabetes portfolios in the industry. Ozempic and Rybelsus have been performing well in the diabetes market. Obesity drug Wegovy has been enjoying increasing demand. Label expansions of diabetes and obesity care drugs in cardiovascular and other indications will likely boost sales. Novo Nordisk raised its 2023 view due to higher demand for Ozempic and Wegovy. Its diversifying efforts to develop new treatments are encouraging. However, stiffer competition from pharma bigwigs like Pfizer, who are likely to eat away from Novo Nordisk’s Diabetes care market share due to serious supply constraints in international markets. Patent expiry and pricing pressure across the diabetes market also remain a woe. Shares of the company have outperformed the industry in the past year. Over the past four weeks, shares have rallied 5.39%, and there have been 2 higher earnings estimate revisions in the past two months for fiscal 2023 compared to none lower. The consensus estimate has moved up as well.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's How Much You'd Have If You Invested $1000 in Novo Nordisk a Decade Ago
For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and industries.
FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks.
What if you'd invested in Novo Nordisk (NVO - Free Report) ten years ago? It may not have been easy to hold on to NVO for all that time, but if you did, how much would your investment be worth today?
Novo Nordisk's Business In-Depth
With that in mind, let's take a look at Novo Nordisk's main business drivers.
Bagsværd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market with a full portfolio of GLP-1 receptor agonists, modern insulins and human insulins. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.
Novo Nordisk operates through two segments: Diabetes and obesity care and Rare diseases. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Rare diseases segment includes hemophilia, growth hormone therapy and hormone replacement therapy.
Novo Nordisk’s most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.
Wegovy, Novo Nordisk’s other obesity care product, was approved by the FDA in June 2021, following which it faced supply issues in the United States, which led to a decline in sales upon launch. However, the issue was resolved by Novo Nordisk, making all dose strengths of Wegovy available in the United States in December 2022. The company is also looking to expand the drug’s indication as an adjunctive treatment for the prevention of major adverse cardiovascular events (MACEs) in adults over a period of up to five years, as well as in the treatment of heart failure and obesity.
In October 2022, Novo Nordisk acquired Forma Therapeutics for $1.1 billion. Forma Therapeutics is a company focused on providing innovative treatment to transform the lives of patients suffering from sickle cell disease (SCD) and rare blood disorders. The acquisition of the company along with Forma’s lead development candidate, etavopivat, complements Novo Nordisk’s vision to accelerate its scientific presence and pipeline in hemoglobinopathies.
Novo Nordisk generated revenues of DKK 177 billion in 2022 compared with DKK 141 billion in 2021. Revenues increased by 26% in Danish kroner and 16% at the currency exchange rate.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Novo Nordisk, if you bought shares a decade ago, you're likely feeling really good about your investment today.
A $1000 investment made in November 2013 would be worth $5,961.03, or a gain of 496.10%, as of November 22, 2023, according to our calculations. This return excludes dividends but includes price appreciation.
In comparison, the S&P 500 gained 152.70% and the price of gold went up 54.56% over the same time frame.
Analysts are forecasting more upside for NVO too. Novo Nordisk beat earnings and revenue estimates in Q3 due to higher GLP-1 product sales. It has one of the broadest diabetes portfolios in the industry. Ozempic and Rybelsus have been performing well in the diabetes market. Obesity drug Wegovy has been enjoying increasing demand. Label expansions of diabetes and obesity care drugs in cardiovascular and other indications will likely boost sales. Novo Nordisk raised its 2023 view due to higher demand for Ozempic and Wegovy. Its diversifying efforts to develop new treatments are encouraging. However, stiffer competition from pharma bigwigs like Pfizer, who are likely to eat away from Novo Nordisk’s Diabetes care market share due to serious supply constraints in international markets. Patent expiry and pricing pressure across the diabetes market also remain a woe. Shares of the company have outperformed the industry in the past year.
Over the past four weeks, shares have rallied 5.39%, and there have been 2 higher earnings estimate revisions in the past two months for fiscal 2023 compared to none lower. The consensus estimate has moved up as well.